Yakira Capital Management’s Estrella Immunopharma Warrant ESLAW Stock Holding History

Yakira Capital Management’s Portfolio ESLAW Stock Details ESLAW Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$3.47K	Sell	46,285 -200	-0.4%	-$15	﹤0.01%	185
2025 Q4	$2.33K	Hold	46,485	–	–	﹤0.01%	183
2025 Q3	$2.41K	Hold	46,485	–	–	﹤0.01%	177
2025 Q2	$2.21K	Hold	46,485	–	–	﹤0.01%	185
2025 Q1	$4.11K	Hold	46,485	–	–	﹤0.01%	172
2024 Q4	$4.27K	Hold	46,485	–	–	﹤0.01%	195
2024 Q3	$4.11K	Hold	46,485	–	–	﹤0.01%	209
2024 Q2	$2.7K	Hold	46,485	–	–	﹤0.01%	241
2024 Q1	$2.39K	Hold	46,485	–	–	﹤0.01%	276
2023 Q4	$1.4K	Hold	46,485	–	–	﹤0.01%	302
2023 Q3	$11.2K	Sell	46,485 -20,300	-30%	-$3.36K	﹤0.01%	242
2023 Q2	$3.5K	Hold	66,785	–	–	﹤0.01%	304
2023 Q1	$6.59K	Hold	66,785	–	–	﹤0.01%	300
2022 Q4	$3.47K	Buy	+66,785	New	+$5.58K	﹤0.01%	327

Other funds holding ESLAW

BFM

Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return

RSWM

Robertson Stephens Wealth Management San Francisco, California $4.06B AUM 32.22% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

SIA

SkyView Investment Advisors Shrewsbury, New Jersey $743M AUM 17.91% 1-Year Est. Return

Whitebox Advisors Minneapolis, Minnesota $8.12B AUM 15.85% 1-Year Est. Return

Clear Street New York $24.6B AUM 56.26% 1-Year Est. Return

Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $69.7B AUM 40.86% 1-Year Est. Return

Yakira Capital Management's ESLAW Position: Q1 2026 in Review

Yakira Capital Management reduced its Estrella Immunopharma Warrant (ESLAW) stake by 0.43% in Q1 2026, selling an estimated $15 and leaving 46,285 shares worth $3.47K. The position accounts for ﹤0.01% of the portfolio, ranked #185.

Yakira Capital Management first reported a position in ESLAW in Q4 2022 and has held it in 14 quarters since. The position peaked at $11.2K in Q3 2023. 8 funds tracked by Wall St. Rank hold ESLAW as of Q1 2026.

Yakira Capital Management held 46,285 shares of Estrella Immunopharma Warrant worth $3.47K as of Q1 2026.
Yakira Capital Management sold 200 Estrella Immunopharma Warrant shares in Q1 2026, an estimated $15.
Estrella Immunopharma Warrant made up ﹤0.01% of Yakira Capital Management's portfolio in Q1 2026, its #185 holding.
Yakira Capital Management first reported a position in Estrella Immunopharma Warrant in Q4 2022 and has held it in 14 quarters since.
Yakira Capital Management's Estrella Immunopharma Warrant position peaked at $11.2K in Q3 2023.
8 funds tracked by Wall St. Rank held Estrella Immunopharma Warrant as of Q1 2026.

Based on Yakira Capital Management's 13F filing for Q1 2026, filed 14 May 2026.